Abstract: Discovering the genes that contribute to complex polygenic diseases represents a significant challenge. Investigating the structural genetic variations associated with these disorders may not be sufficiently informative about vulnerability genes modulated by the environment. Characterizing gene expression patterns does not identify the primary differences in gene structure. The convergence of global screening of gene expression patterns with extensive structural genomic information may be necessary to identify the gene clusters that contribute to these pervasive diseases. These integrative efforts, though promising, are in their early phases and will require further refinement.
INTRODUCTION
It is now generally accepted that many of the most pervasive illnesses are rarely inherited in a Mendelian fashion and that they are polygenic in etiology, with significant gene-environment interactions. As such, understanding the genetics of complex diseases is a focus and challenge for medicine. Identifying the genes that contribute to or modify complex inherited diseases will serve as a basis for both the pathophysiological understanding of these diseases and the discovery of novel drug targets.
Two general approaches have been applied to the discovery of genes for complex diseases -the functional approach, including the candidate-gene approach, and the positional approach. For "functional cloning" approaches, the identification of candidate genes is based on a series of 'educated' guesses without reference to chromosomal map position. The major shortcomings of these methods is the requirement for a priori knowledge of gene function and the expectation that critical genes have a detectable impact on the phenotype. "Positional cloning" approaches locate the gene solely on the basis of map position and obviate the need for a priori knowledge of gene function. In positional cloning, the identification of the culprit gene within the relevant region is a major challenge. Recently, the "positional candidate" method [1] -which is based on the combination of the identification of a chromosomal subregion or quantitative trait locus (QTL), usually by linkage analysis, with an examination of the region for attractive candidate genes -has been used. Most prominently, this has successfully identified point mutations in the RET protooncogene, which cause multiple endocrine neoplasia type 2 [2] , and mutS, hPMS1, hPMS2 and mutL, which cause hereditary non-polyposis colon cancer [3] [4] [5] . However, the weakness of this method is that it relies on the density of the transcript map and on a priori knowledge of gene function to identify good candidates within the region of interest. Moreover, the structural genetic approach does not address *Address correspondence to this author at the Department of Medicine, University of Illinois at Chicago, 840 S. Wood St., Chicago, IL 60612, USA; Tel: 312-569-6606; Fax: 708-594-2907; E-mail: Rdanziger@aol.com the biological path(s) that leads from a normal allelic variation to vulnerability to an illness.
While the above strategies focus on discovering differences in gene structure, recent approaches have evolved to globally assess gene function, including transcriptional profiling and alterations in protein levels. These methods are still in their early phases and continue to require technical and analytical refinements. They offer the significant advantage of examining function specifically in the affected tissue, thereby defining a profile of altered activity that results from the interaction of genes and environment. By the same token, the observed alterations in gene function are, in the majority of cases, not likely to be primary or directly attributable to genetic variations. Moreover, many might also be secondary to the disease process rather than its cause. Thus, transcriptional profiling alone cannot define the genetic etiology of complex disorders.
Bringing the global functional screening methods, such as transcriptional profiling, together with genomic mapping and positional cloning could theoretically combine the strengths of both approaches and overcome their individual limitations. However, this is a demanding process requiring both genetic expertise and specific knowledge of the organ or physiological system involved in the disorder. Its progress depends either on the availability of appropriate human tissue or on an informative animal model of the disease. It will also depend on the power of the individual technologies and our ability to analyze, mine and interpret the resulting information.
Here we review how the integration of transcriptional profiling and genomics is being used to investigate the genetics of three common, complex phenotypes/disorders: blood-pressure control and hypertension; cell growth and cancer; and central nervous system (CNS) function and neuropsychiatric disorders. The reviewed approaches are diverse -they use either animal models or direct human studies, and they are at various phases of progress. The fact that these three areas sometimes lack direct parallels is reflective of the state of the field where each class of disorders offers unique challenges and may require somewhat different strategies. But from the combined picture emerging from these areas we can glimpse the range of possibilities that this intersection of approaches can provide. We can also point to the limitations of this strategy that need to be overcome in order to ensure significant progress.
BLOOD-PRESSURE CONTROL AND HYPERTEN-SION
Blood pressure is a complex quantative phenotype. The greatest insights into the genetics of hyptension have been in the Mendelian forms [6] . So far, the identification of candidate genes has been most successful for genes for which there is a priori knowledge of relevance to the pharmacology and physiology of blood-pressure control, e.g., those in the renin-angiotensin-aldosterone (RAS) and adrenergic signaling pathways [7] .
Salt-Sensitive Hypertension
Although salt is considered a major environmental risk factor for hypertension, there is significant inter-individual variability in the blood-pressure response to salt, which indicates that it has polygenic underpinnings. So far, a few genes (including aldosterone synthase and 11-beta hydroxylase, the epithelial sodium channel (ENaC), the mineralocorticoid receptor and the serine-threonine kinases, WNK1 and WNK4) have been linked to rare Mendelian forms of human hypertension that show some salt sensitivity [8] [9] [10] [11] [12] [13] [14] [15] . However, the candidate genes that have been tested for salt-sensitivity and evaluated to date do not fully explain salt-sensitive hypertension. The need to identify novel genes that have not been considered and to highlight specific genes within regions that have been identified by physical-mapping strategies led to the use of the integrative approach of transcriptional profiling in conjunction with QTL analysis in animal models.
Studies of salt-sensitive hypertension have capitalized on several artificially selected, inbred hypertensive strains of rats, in which congenic constructs and genome-wide scans have been used to identify QTLs for blood pressure. One of the most commonly studied strains is the Dahl salt-sensitive (SS) rat strain, which is an inbred strain that was artificially selected from progenitor Sprague Dawley rats to obtain the maximum blood-pressure response when given a high-salt diet [16] . This is considered as a "renal model" of saltsensitive hypertension, as cross-transplantation" experiments have shown that the kidney confers salt sensitivity [17] . One of the genes for which there is evidence for linkage of mutations with altered steroid biosynthesis and blood pressure in the Dahl rat of is 11 beta-hydroxylase [18] .
Congenic strains and genome-wide scans of the Dahl rat have identified up to 16 blood-pressure QTLs [19] [20] [21] . A major challenge is to identify the genes within these QTLs that are associated with salt-sensitivity. Genes for which the renal transcript abundance changes during normal adaptation to a high-salt diet will include those that are important for salt adaptation, that are induced by hypertension, and that are unrelated to salt-adaptation and blood pressure control. The working hypothesis was that genes that are most likely to be important in the pathogenesis of salt sensitivity are those that do not undergo the same change in abundance in animals/strains that develop hypertension when given a high salt diet. Gene transcripts, identified by transcriptional profiling, that had different abundances in the Sprague Dawley rats, a normotensive, salt-resistant strain, on two different salt diets included three that are elements of the RAS system: renin; serum and glucocorticoid kinase 1 (SGK1), which activates the epithelial Na channel (eNaC); and aminopeptidase N, which metabolizes angiotensin III to IV (a blood-flow regulator). Two of these transcripts, SGK1 and aminopeptidase N, did not undergo the same change in abundance in Dahl SS rats, suggesting that they may be good candidate genes for salt-sensitive hypertension. SGK1 and aminopeptidase N genes were mapped, using radiation hybrid mapping, with respect to reported blood-pressure QTLs in the Dahl SS rat [22] [23] . Each mapped to QTLs, determined using congenic Dahl strains, on chromosome 1. A polymorphism of the aminopeptidase N gene that is preferentially expressed in the Dahl SS versus Sprague Dawley and Dahl salt-resistant (SR) (the parallel strain selected for salt-resistance from progenitor Sprague Dawley) rats has recently been identified (R.D., unpublished observations). Physiological validation of these genes is now being pursued with protein and activity measurements [23] .
In an analogous strategy, Liang et al. [24] compared the transcriptional profiles of the renal medulla from Dahl SR rats with Dahl SS rats that were consomic for chromosome 13 from Brown Norway (BN) rats, another salt-resistant strain, on high and low salt diets. Using this four-way comparison, 60 genes were identified. The fact that only a few of these genes (such as 11 beta-HSD type 1, NGFinducible anti-proliferation protein, 1-Cys peroxiredoxin, kynurene 3, hydroxylase), which have distinct temporal patterns of expression, map to rat chromosome 13 could be caused by several mechanisms. Genomic differences on chromosome 13 and the products that result could be regulatory factors that directly influence the expression of genes on many chromosomes. These genome-wide gene interactions could also be indirect; through downstream signaling pathways, or as a result of feedback regulation by functional alterations. In addition, the possibility of residual BN alleles on chromosomes other than chromosome 13 in SS-13BN/Mcw rats (bred at the Medical College of Wisconsin, Milwaukee) cannot be excluded.
Lee et al. [25] sought analysis of differential gene expression patterns in the kidneys of a panel of eight congenic strains, each of which carries a different low-BP QTL allele with a genetic composition that is otherwise similar to that of the hypertensive Dahl salt-sensitive (S) rat strain. Seven out of 37 differentially expressed genes were mapped to congenic regions carrying BP QTLs, but only one of these genes, L-2 hydroxy acid oxidase (Hao2), showed the congenic strain-specific pattern of differential kidney gene expression predicted by its chromosomal location.
Thus, transcriptional profiling has highlighted a number of genes that encode proteins both within and outside the RAS pathway. In each study, genomic mapping data was used to filter the genes by selecting only those which are most likely to co-segregate with hypertension and thereby provide a small group of candidate genes for further testing.
Salt-Independent Hypertension
The identification of candidate genes for salt-independent hypertension by contrasting transcriptional profiles of spontaneously hypertensive (SHR) and normotensive (WKY) rat strains, has led to the identification of 46 differentially expressed genes. Two of these, i.e., monocarboxylate transporter 1 and glutathione S-transferase Y(b) subunit, significantly impact diastolic blood pressure in F2 crosses of the rats [26] . This points to the potential value of integrating transcriptional profiling with other forms of genetic analysis, e.g., backcrosses, to narrow down the number of genes identified by transcriptional profiling for further consideration. The fact that none of the genes mapped to QTLs for systolic hypertension demonstrates one of the limitations of this method (see below).
Stroke Related to Hypertension
Fornage et al. [27] used an analogous strategy to determine the genes that are associated with stroke in hypertension. They compared the transcriptional profiles of brains from spontaneously hypertensive rats (SHR) and stroke-prone SHR rats (SHRSP), a strain that was developed by selective breeding for the development of cerebrovascular injury at a high frequency from the SHR rat [28] . Out of 117 differentially expressed unique genes or expressed sequence tags (ESTs), five -DOC2A, natriuretic peptide precursor type A, Kcnab2, CaMK2 inhibitor, and casein kinase 2 -mapped to stroke QTL regions. Other genes that encode multiple kinases of the MAPK/AKT signaling pathways, including JNK2, AKT2, and P13K, did not map to reported QTLs. Thus, by integrating transcriptional profiling with mapping data, 2 of 117 genes have been highlighted as candidates. Furthermore, other genes among the 117 may also precipitate cosegregation analysis of regions to which they map, especially since a priori mapping in the SHR is incomplete.
In a study by McBride et al [29] a congenic strain that exhibited a reduced systolic and diastolic blood pressures compared to the SHRSP rat in which a region of chromosome 2 from the normotensive Wistar Kyoto (WKY) strain was introgressed into the genetic background of the SHRSP rat, glutathione S-transferase µ−type 2, a gene mapping to the congenic region and involved in defense against oxidant stress, was differentially expressed.
These varying strategies, all dependent on various animal models of hypertension have yielded novel candidates that now can be tested in various types of human hypertension.
CANCERS AND TUMOR MODIFIER GENES
The risk of cancer is associated with both environmental exposure and genetic predisposition, i.e. gene-environment interaction. For example, lung cancer has frequently been cited as an example of a malignancy that is solely determined by the environment, and the risks associated with cigarette smoking, and certain occupations, such as mining, shipbuilding and petroleum refining, are well established [17] [18] [19] [20] [21] [22] [23] [24] . However, there is also strong evidence for genetic susceptibility. Studies of familial aggregation of lung cancer suggest that genetic factors are involved in human lung tumor development [30] [31] [32] [33] [34] [35] . Specifically, segregation analyses of lung cancer proband families indicate that a Mendelian codominant inheritance of a rare major autosomal gene is involved [36] . This locus has been shown to account for 69%, 47%, and 22% of the cumulative incidence of lung cancer in patients at age 50s, 60s, and 70s, respectively [36] . Since genetic heterogeneity and enormous variation in exposure levels to tobacco and other environmental agents make it difficult to identify lung cancer susceptibility loci in humans, inbred mouse models offer an effective means of identifying candidate lung cancer susceptibility loci.
Numerous lung tumor-related QTL have been found in various animal models [37, 38] . Susceptibility to chemical induction of lung tumors in mice varies according to the strain [39] . Genetic linkage analyses using various mouse crosses have revealed a series of pulmonary adenoma susceptibility (Pas) genes, e.g. Pas1 (chromosome 1), Pas2 (chromosome 17), and Pas3 (chromosome 19), and pulmonary adenoma resistance (Par) genes, eg. Par1 (chromosome 11), Par2 (chromosome 18), Par3 (chromosome 12), and Par4 (chromosome 4) [37] [38] [39] . In the past decade, several research groups have been actively pursuing the identification of the genes that underlie these lung tumor QTL [37] [38] [39] . However, the identification of these candidate genes has proven rather difficult. One obstacle is the fact that several hundred genes can lie in a 20-30 cM QTL region. Fine-mapping studies are typically timeconsuming and labor-intensive. Evaluation of differential gene expression and nucleotide polymorphism of such a large number of genes can also be a significant challenge using a conventional approach. The useof microarray technology in combination with the recently completed mouse/human genome sequences has greatly facilitated the identification of modifier genes in a mapped QTL [40, 41] . Indeed, candidate lung tumor modifier genes whose expression varies between parental strains have been identified using transcriptional profiling in two independent studies [42, 43] .
Recent studies undertook the profiling of lungs from mouse strains with variable susceptibility to lung tumor development as a means to identify, within known QTLs, candidate genes responsible for susceptibility or resistance to lung cancer [42] . The work focused on eight mapped mouse chromosomal regions linked with lung tumor susceptibility (Pas1-4) or resistance (Par1-4). High-density oligonucleotide arrays were used to measure the relative expression levels of >36,000 genes and ESTs in lung tissues of A/J, BALB/cJ, SM/J, C3H/HeJ, and C57BL/6J mice. In total, 50 differentially expressed genes, whose pattern of expression in the strains was also consistent with that of the reported association with cancer, were found in the lung cancer susceptibility QTLs. As A/J is the susceptible strain and C57BL/6J the resistant one, tumor suppressor candidates will have shown higher expression in C57BL/6J, while oncogene candidates will have shown higher expression in A/J for Pas1-4 loci. Genes that show differential expression are Cyclin D2, high mobility group protein 2A4, Cyclophilin H, Protein tyrosine phosphatase BK, RecQ protein-like, ECA39 protein, and Hes related protein. Pas2 QTL is located at the H-2 locus whose haplotypes correlate with the incidence and multiplicity of mouse lung tumor induction. Candidates that show differential expression are Tapasin, KE2, H2-K region expressed gene 6, Notch4, Regulator of cullins 1, MHC psoriasis candidate protein, Histocompatibility 2M region locus 9, Eclonucleotide pyrophosphatase/ phosphodiesterase 4, Heterogeneous nuclear ribonucleoprotein K, and CDC5-like. Pas3 candidates include cdc25 homologue A (S cerevisiae), semopharin 4G, golgi specific brefeldin A resistance factor 1, adrenergic receptor (beta 1). Pas4 candidates are tyrosine kinase adaptor protein 1, parathyroid hormone receptor, Wiskott-Aldrich syndrome homologue binding protein, SMARC D3, cyclin dependent kinase 5, G(i) alpha 2, stromal antigen 1, and similar to topoIIBP.
The identificationof these candidate genes is an important first step towards the determinationof the genes that are responsible for a given lung tumor QTL. Real-time RT-PCR is usually used as the second step to corroborate the candidate genes that emerge from oligonucleotide arrays. The definitive confirmation of the real gene(s) will require both in vitro and in vivo studies. In vitro studies involve the characterization of allelic differences in cell proliferation, cell cycle, and apoptosis, which will provide important clues as to which candidates may potentially be important in lung tumorigenesis. The ultimate proof that a candidate gene is actually the gene for the tumor QTL may require targeted allelic substitution (knock-in mice). In the resulting mice, only the putative allelic variant from a donor (inbred strain) replaces the homologous allele in a recipient inbred strain and results in a change in lung tumor susceptibility in the recipient strain.
Another approach is to first identify all differentially expressed genes in strains of mice with known lung tumor phenotype, followed by mapping of the identified genes to their chromosomal locations of the lung cancer modifier loci. Using this approach, Gariboldi et al. [43] analyzed gene expression in the lungs of 16 inbred strains of known susceptibility/resistance to lung tumorigenesis using cDNA microarrays containing 19K full-cDNAs (all of the genes and all of the isoforms of genes in the mouse genome were not represented on these microarrays and thus the candidates may not be in the set that was profiled) [44] . At least 10 genes have shown functional role in cancer growth, differentiation or progression. The remaining genes show potential involvement in cancer. For example, myeloid cell leukemia sequence 1, major vault protein, alpha-methylacylCoA racemase, plastin, and Arhc ras homolog gene familymember C are tumor markers, the altered expression of which is associated with tumor development and progression [44] . Among the 91 genes identified, the genes mapping closer to lung cancer modifier loci were: Hypothetical protein FLJ11088 at the Pas1 locus, Stard3 START domain containing 3, Krt1-10 Keratin complex 1 (acidic) gene 10, and Homolog to high sulfur protein B2E at the Par1 locus. These results suggest that the gene expression profile of normal lung tissue can identify highly relevant candidates for the genetic predisposition to lung tumorigenesis in mice without the information from prior QTL mapping studies.
As shown in Table 2 , candidates from the above study [43] are part of several cellular signaling pathways, including apoptosis, cytoskeletal organization, chromatin modeling and the cell cycle. As such, susceptibility and resistance to cancer involves a constellation of factors, some interacting, and failure of any one can lead to carcinogenesis.
However, there is an intrinsic problem in these two experiments of using gene expression profiling to identify candidate lung tumor susceptibility genes in mice. Normal lung tissue contains more than 30 different cell types. The cells that may develop into tumor cells, i.e. the alveolar type II cells and Clara cells, represent a very small fraction of the cells in normal lung. Thus, the bulk of the expression measured comes from cells not involved in cancer development. There is a possibility that some of the differentially expressed genes specific for tumor susceptibility are not readily detectable due to the apparent dilution of the cells related to tumorigenesis. Future studies should use the pure Type II cells or Clara cells from lungs of the parental strains of mice to overcome this problem. Finally, it remains to be seen how many of the mouse susceptibility genes will really have human counterparts that will be useful for diagnostic or therapeutic purposes.
BRAIN-RELATED GENES: FOCUS ON NEUROPSY-CHIATRIC DISORDERS
Brain-related complex genetic disorders offer unique challenges, as brain function depends on the activity of neural circuits that include multiple cell types interconnecting across brain regions and requiring the interplay of numerous signaling pathways. Moreover, the brain is programmed to change structurally and functionally as a function of experience. This "neural plasticity" allows experience-based learning and memory and is associated with significant changes in gene expression patterns across the relevant circuit. These characteristics make it difficult to draw a one-to-one connection between the sequence variations of a single gene and a given function or disorder, and underscore the importance of considering integrated brain activity as the central intermediary between genetics and behavior.
These considerations are particularly important in certain psychiatric and neurological disorders such as schizophrenia, bipolar illness, Parkinson and Alzheimer Disease that are mediated by specific neural circuits, are highly dependent on the environment and show a complex lifetime course. But in spite of the likely heterogeneity of the susceptibility genes for these disorders, a common "neural phenotype" likely exists that represents the signature of the disease on the brain. This would represent an overall pattern of gene expression within a relevant circuit as a result of altered activity of both the vulnerability genes and their downstream targets. Thus, it is reasonable to use a convergent approach that combines functional genomic strategies with classical genetic strategies to uncover this "neural phenotype" that defines a neuropsychiatric disorder, and devise appropriate strategies for disease treatment and prevention.
Another challenge is that many brain disorders (particularly psychiatric) are difficult to model in rodents. While there are animals that may be prone to hypertension or cancer or seizures, there are no known rat or mouse strains that are prone to psychosis, an essentially human disorder. However, some animal models can mimic specific aspects of a. Candidate region of each QTL was based on results of interval mapping studies. The position information for each QTL is added based on the previous interval mapping results (representing ≥ 95% confidence intervals based on the ≥ 2 LOD score significant threshold and 1-LOD-score-fall supporting interval. b. Candidates were generated by the recent microarray studies [42, 43] . The Pas3 (chr. 19) and Pas 4 (chr. 9) datasets [42] were not included in this review due to their undefined QTL positions. c. All of chromosome positions were based on the latest Celera mouse genome database (released on April 4, 2004) . or rat University of California Santa Cruz (UCSC) Genome Browser. d. The Peak of LOD score for the Par4 is located in the middle of interval and no marker was designated. e. Genes to not map to QTL based on UCSC browser even though originally reported to do so, the human disease. For example, the increased activity associated with mania is modeled in animals with psychostimulants like amphetamine [45] . Thus, while functional genomics in animal models may be suggestive, direct studies in humans are essential.
Clinical neuroscience has recently entered a new phase of relying on convergent approaches to implicate specific genes in the major neurological and psychiatric disorders. Here we focus on a few recent findings that rely primarily on genomic data from human postmortem tissue, which exemplify this approach. However, we will include an example from bipolar illness research that started with an animal model and used functional genomics to identify a novel candidate that was then pursued in human association studies.
New Genes for Schizophrenia
Schizophrenia affects approximately 1% of the population and has a strong genetic component, with estimates of heritability exceeding 50% [46] . But it is only during the last three years that any susceptibility genes have been implicated in schizophrenia. Genome wide scans had linked numerous chromosomal loci to the disease. A metaanalysis by Badner and Gershon [47] found the strongest evidence of schizophrenia susceptibility loci on 13q and 22q (shared with bipolar illness) and on 8p. Recent association studies of genes within the linked regions have yielded exciting discoveries. Prominent among them is the identification of Neuregulin (NRG1) as a susceptibility gene that has been replicated in a number of cohorts [48] [49] [50] [51] . Also receiving much attention is Catecholamine-O-Methyl tansferase (COMT), a functional candidate that has recently been associated with schizophrenia in an Ashkenazi population [52] . A specific COMT allelic variation associated with schizophrenia has been shown to alter the activity of the enzyme, to be correlated with decreased cognitive function [53] and with the induction of another critical enzyme (tyrosine hydroxylase) in a circuit implicated in the psychotic symptoms of schizophrenia [54] . A handful of other schizophrenia genes have recently been identified through these classical genetic methods [55] .
Recent years have ushered in the use of genomics to describe the "neural phenotype" that is associated with schizophrenia. Although gene arrays offer a number of challenges for studying the neural systems [56] , and while there are many difficulties associated with the study of postmortem human brains, such as the effects of agonal state and tissue pH [57] , the approach holds promise for brain disorders especially if based on careful characterization of control brains and combined with validation strategies such as Real-Time PCR and in situ hybridization [58] . A number of novel candidate genes have emerged from the body of genomic studies focusing on schizophrenia [59] [60] [61] [62] [63] [64] [65] [66] . Results reveal genes expression changes relating to oligodendrocytes and myelination, cytoskeletal organization, energy metabolism, synaptic function and plasticity and intracellular signaling pathways [67] , and some of these genes and pathways have been replicated by independent laboratories [63, 68, 69] . Among the neurotransmission/signaling genes, two have been pursued from gene expression to gene structure: RGS4 and NPY (Boxes 1 and 2) .
A Novel Candidate in Bipolar Illness
Although few animal models capture the full extent of major psychiatric disorders, some models focus on specific but central symptoms as a means of investigating underlying mechanisms. This affords the opportunity to discover novel genes in animal models and test them in humans. Niculescu et al. [45] used a single injection of methamphetamine in rats to model the hyperactivity that is associated with mania. These authors then carried out oligonucleotide microarray studies in brain regions that are associated with emotional reactivity-contrasting treated and untreated animals. Genes that were significantly altered were cross-matched against human genomic loci associated with either bipolar disease or schizophrenia. A G protein-coupled receptor kinase (GRK3) emerged as the gene most significantly induced by methamphetamine in rat and is present in one of the strongly implicated human loci (22q12). The same group then studied GRK3 in transmission disequilibrium analysis in bipolar families. They identified several SNPs in the promoter region of this gene and provided evidence for a significant association between one of these SNPs (P-5) and bipolar illness. The authors suggest that GRK3, given its involvement in the desensitization of G protein receptor, may be one of the genes that can alter signaling in the brain of bipolar subjects [70] . Whether the SNP in question is indeed associated with altered expression of GRK3 or downstream molecules in human brain, and whether altered GRK3 activity can impact animal behavior remains to be determined.
Genomics for the Study of Alzheimer and Parkinson Disease
A number of genes have been implicated in the increased risk for Alzheimer Disease (AD) and Parkinson Disease (PD) [71, 72] . But beyond the risk of getting the disease, the age-at-onset of these neurological disorders can vary widely and is also genetically determined. Previous work demonstrated that a common locus (10q) controls the age-atonset for both AD and PD 74. However, this 15-cM region includes a large number of genes. Thus, Hauser et al. [73] used what they term 'genomic convergence' -the combination of gene arrays with genetic association data -to select the genes of interest. They carried out transcriptional profiling on hippocampi obtained from AD patients and controls. Four genes that were significantly altered in expression between cases and controls were found to map to the 10q linkage region. However, only one of these genes was significantly associated with the onset of the disease in the follow-up association studies. Allelic association studies for age-at-onset effects in AD and PD revealed a significant association for glutathione S-transferase, omega-1 (GSTO1)] and uncovered an association with a second transcribed member of same class, GSTO2 located next to GSTO1 [74] . Interestingly, these genes were only associated with age-atonset of both diseases but not with overall risk of developing either disorder. While the functions of GSTO1 and GSTO2 are not well understood, there is evidence that they may play a role in the biotransformation and disposition of drugs and products of oxidative stress, as well as in the posttranslational modification of interleukin-1β {1742}. Thus this novel discovery is in line with pre-existing hypotheses about the possible role of oxidative stress and inflammation in neurodegenerative disorders.
These early results with neuropsychiatric diseases exemplify the promiseof combining functional genomics with QTL analysis to uncover novel molecular candidates for the susceptibility to these illnesses. These studies have face validity in that they are consistent with our broad notions of the illnesses by revealing genes related to signaling or neuronal plasticity. Yet, they open new frontiers for research in that the specific genes they reveal are not necessarily the obvious candidates that might be selected based on prior knowledge.
So, as previously suggested by neuroscientists, the psychiatric disorders are diseases of neurotransmission probably involving several transmitter families including monoaminergic, peptidergic, GABAergic and Glutamatergic mechanisms, as well the modulation of the duration or efficacy of synaptic transmission. However, the specific molecules relevant to the illness (NPY, NRG1, GRK3, RGS4) may not have been the first in line for testing if it were not for the genomic studies. Similarly, while there was evidence of inflammatory, oxidative, and apoptotic mechanisms involved in neurodegenerative disorders, the specific genes uncovered (e.g. GSTO1 and GSTO2) would not have been obvious candidates. However, it is important to note that we have not defined clear criteria to ascertain whether we have yet captured the most important candidates or combinations thereof.
Genomic Studies in Brain Still have Many Untapped Directions
The genes discovered so far appear to each explain a small percentage of the variance or likelihood of expressing a particular disorder. Knowledge of neural circuitry can be combined with genomic strategies to further focus on the critical genes. For example, if a particular splice variant of a gene is present in a circuit implicated in the illness, it would be this particular variant that might become the focus of the genomic and genetic investigation. Moreover, genomic strategies can reveal ensembles of altered genes, and these may be seen in anatomically distinct components of the neural circuit (e.g. alterations in a neurotransmitter gene expressed in the presynaptic neurons of one brain region and in its receptor expressed in the postsynaptic neurons of the target region). Such combinations of altered gene expression involving multiple genes within a relevant circuit would be informative in the search for novel susceptibility genes that are altered at the structural level. The role of selected and inbred rodent models for the study of neural disorders is also critical both to identify novel genes in the animal models or to follow up on the discoveries made in human. Thus, the convergence of neurobiology, genomics and genetics is likely to prove very powerful in pinpointing the susceptibility genes and in establishing the neural phenotype associated with the emergence and progression of brain disorders.
Comparison with other Approaches and Future Directions
The examples described above broadly capture the current status of three fields using the integration of genomics and transcriptional profiling to discover genes that contribute to complex disorders. They point to both strengths and limitations of this approach and underscore not only the promise but the technical and conceptual challenges that face the field.
Strengths
The work to date suggests that combining transcriptional profiling with genetic linkage analysis in order to identify novel candidates genes is likely to be more powerful than previous strategies that rely on either approach alone. Integrating profiling data with physical mapping data not only removes genes that are not good candidates, but also circumvents the fine-mapping or interval sequencing that is needed to identify candidate genes within QTLs.
Expression profiling can potentially capture the effect of interactions that alter gene expression, either among the vulnerability genes or between them and the environment. In doing so, expression profiling may point to some genes that would have never been investigated otherwise, However, as
This regulator of G-protein signaling acts across many receptors as a GTPase accelerating the dissociation of G-alpha bound GTP and shortening the signaling. Decreased expression of RGS4 in the dorsolateral prefrontal cortex of schizophrenic subjects was first discovered by microarray and confirmed by in situ hybridization [60] . Since this gene maps to 1q21-q22, a locus linked to schizophrenia, it was tested as a candidate gene in two US populations and one Indian population using both linkage analysis and a population case/control approach [107] . Four SNPs located in the first intron showed significant association in the family-based tests. Moreover, families with affected siblings showed greater allele sharing and identity by descent. However, the case-control population-based comparisons did not yield significant results. While the global association for all 4 SNPS was highly significant, the transmitted alleles and haplotypes differed across populations even within the United States. Thus, whether this truly reflects a vulnerability gene in schizophrenia remains to be fully established.
Box 2: NPY
Neuropeptide Y (NPY), a peptidergic neurotransmitter, may represent the best example of implicating a gene in schizophrenia by moving from gene expression to genotype. In some ways, NPY can be construed as a functional candidate since alterations in NPY function in schizophrenic cortex was first discovered by examining peptide content [110] and other findings have suggested potential alterations in NPY release in schizophrenia. However, it was the more recent genomic findings that propelled its examination as a susceptibility gene. Kuromitsu et al [111] used DNA microarrays and reported that NPY mRNA levels are significantly decreased in the prefrontal cortex of subjects suffering from both schizophrenia and bipolar disorder. An association study in a Japanese cohort [108] led to the discovery of a novel polymorphism in the promoter region of the NPY gene, whereby the -485 C to T variation results in a significant decrease in promoter activity. The -485T allele was overly represented in the disease group (P=0.004), suggesting that it may decrease NPY expression in brain and confer susceptibility to schizophrenia. discussed below, sophisticated informatics and statistical analysis strategies are needed to define the subsets of genes worthy of such pursuit.
Given the amount of information that is obtained using an integrated strategy of transcriptional profiling and positional cloning, this approach to studying the genetics of complex disorders may be fairly economical in terms of efficiency and cost, specifically as it can circumvent the need for individual gene-by-gene testing to determine diseaserelated changes. In addition, the expense of transcriptional profiling continues to drop, which makes it both more accessible and feasible for the study of larger populations. For the most part, the first level of validation of candidate genes that are identified by transcriptional profiling is no different than it is for candidate genes that are identified by other methods -requiring, in the case of animals, the development of subcongenics, transgenics, and knockouts; and in the case of humans, identification of polymorphisms, linkage and SNP analysis. However, understanding how the interaction of multiple genes results in disease vulnerability is likely to be more demanding.
Technical Limitations
An important limitation of transcriptional profiling is false positives (10-20% in our experience; R.D., unpublished observations), which necessitate the validation of transcriptional profiling results. Managing false positives can be accomplished in several ways, including performing experiments in triplicate and confirmation by traditional approaches, e.g., RT-PCR or Northern blot analysis or in situ hybridization, or by newer approaches that compare transcriptional profiles of DNA and oligonucleotide microrarrays or microarrays from different manufacturers.
The greatest limitation of approaches using transcriptional is lack of capture of all the genes that may be important (false negatives). The value of the transcriptional profiling is contingent on the number of genes and the number of different isoforms of genes, e.g., splice variants, represented on the microarray. Differences in gene expression levels might not be detected due to a lack of sensitivity for genes with low levels of expression, especially in a highly heterogeneous tissue such as the brain, in which many critical genes are expressed at low levels or in a very region-and cell-specific manner [75] . In addition, gene transcripts may be relevant to a phenotype in a tissue or celltype not profiled. Moreover, polymorphisms not affecting transcript abundance, including those that lead to functional change in protein, alternative splicing, post-translational changes, and translational efficiency, will not be selected or highlighted by transcriptional profiling. Cell sorting or cell capture strategies focusing on the tissue types of interest, Improved gene arrays and new profiling technologies that allow the identification of SNPs and sequence differences may provide power in these areas in the future.
A limitation unique to postmortem human tissue is that the mode of death can affect gene expression, not randomly but in a systematic manner that can bias the results [57] . The effects are biologically interesting in pointing to the impact of certain agonal factors on gene function in particular tissues, but they can be dramatic and can therefore mask the gene expression changes associated with the disease.
Finally, analysis of data deriving from microarray technology represents an ongoing challenge. One needs to use the appropriate statistical tools to manage the issues of false positives and false negatives, to normalize data across samples and experiments, and to address problem of detection sensitivity and reliability [76] . These issues become particularly thorny when one is interested in changes of small magnitude, especially for genes that are near the limits of detection sensitivity, as is often the case for brain studies. However, there are also some increasingly sophisticated strategies that analyze the coordinate changes in functionally related genes. This allows the detection of alterations in gene ensembles, even when the individual changes are modest, and allow one to assess whether the overall ensemble is statistically significant [77, 78] . However, for these more powerful statistical approaches to be truly effective, they need to rely on increasingly more sophisticated ontological annotations of what constitutes ensembles of genes, not only in classical metabolic pathways, or even in intracellular or extracellular pathways, but also in physiological systems including neural circuits.
Conceptual Challenges
While the technical concerns are still significant, they are likely surmountable in whole or in part. The largest challenges facing the field of complex genetics are conceptual or strategic, and many begin after the putative novel candidates have been discovered. For Mendelian disorders the identification of the relevant gene represents a starting point for investigating the function of that gene, its role in the pathophysiology of the illness and its potential as a direct or indirect target for treatment. While each of these endeavors can be arduous, the overall research strategy is conceptually straightforward. By contrast, for complex genetic disorders, there are significant uncertainties at every step.
Firstly, even if we use the integrative approach discussed here, how do we know that we have identified all the key genetic players? For instance, when is it legitimate to say that the critical genes for susceptibility to Alzheimer's disease have been identified and the field can move on to study their mechanisms of action?. The answer might be that we will know it when we have accounted for a significant percentage of the variance-i.e. when we can statistically explain say over 90% of the cases based on combinations of identified vulnerability genes. Since we do not have yet a case of a complex genetic disorder where this has been reached, it is hard to determine how readily achievable this goal is. Some allelic variations may well contribute to a large proportion of the variance. But there will likely be others that may not be detected by standard strategies and that are nevertheless critical to discover, either for a subset of the population, or in combination with some other genes where they play a pivotal modifier role.
The other key issue is addressing the central characteristic of complex disorders-gene-gene interactions. Here again, thoughtful statistical analyses will be required.. Increasingly sophisticated mathematical strategies are being used for determining epistasis [79] [80] [81] . A particular challenge arises in discovering interactions when the main effects of the potential interacting genes or loci are not significant in themselves. This is where the gene expression profile, by pointing to ensembles of activity, with participating genes located in different loci, may help in the selection of combinations to test for epistasis.
It will also be critical to consider the animal models that will be required for testing the function of the multiple genes. The strategy for Mendelian disorders is to create knockout animals, or knock-in animals that harbor that mutation and use them as models. For studying complex disorders, animal models would be required that also address the issue of interactions. It may be possible to compare inbred strains, e.g., hypertensive rats, to examine differences in transcript abundance that may arise from epistatic interactions, both within and between regions of interest [82] , and to study allele fixing in the process of breeding. Many rat strains are available and may have undergone genetic shift with outbreeding, e.g., the Sprague Dawley rat, and different inbreeding, e.g., Lewis rat. Further strategies, e.g., sub-congenics, double congenics, can be used to address these issues [83] [84] [85] [86] . This is especially important when genome-wide scans are used due to the imprecision and influence of factors such as age, sex, and diet on QTLs mapped solely by linkage analysis [87] .
The most direct proof that the combination of identified genes is necessary and sufficient for causing vulnerability to the disorder may necessitate the creation of transgenic animals with alterations of multiple genes (complex transgenics). Ideally, these animals would express the relevant allelic variations in more than one combination, representing the combinations most commonly seen in human populations. One would then ascertain how the combinations of all or a subset of those genes affects gene expression and function in the relevant tissue, and how this in turn results in vulnerability to specific environmental factors.
Testing of the role of individual or combinations of genes in disease vulnerability in humans will also require novel strategies, including better characterization of the clinical phenotype [88] and testing under different environmental conditions that would uncover the interaction of that environment with a given gene or set of genes [89, 90] .
In summary, the integration of transcriptional profiling with physical mapping data is proving useful in identifying candidate genes and gene patterns for some of the most challenging complex diseases. In addition to hypertension, cancer and brain disorders, ongoing applications of this strategy include other polygenic disorders, including arthritis, asthma, and inflammatory bowel disease [91] [92] [93] [94] [95] . As global profiling techniques become more accurate, as linkage analysis and genome-wide scanning improve, as the informatics and data analysis strategies become more sophisticated and as the conceptual challenges are confronted, these approaches should yield significant breakthroughs in understanding the biology of complex genetic disorders.
